Search
Copyright © 2024 ALM Global, LLC. All Rights Reserved.
Credit: New Africa/Adobe StockOver 40% of people in the U.S. are living with obesity and over 11% have Type 2 Diabetes. Metabolic disease is a public health crisis that is driving unsustainable health care spending. Diabetes care alone now exceeds $410 billion annually, with much of that burden shouldered by employers, who cover direct costs like medication and treatment, and individuals who face expensive co-pays and rising health insurance premiums.
GLP-1s have introduced both opportunity and complexity to this already convoluted landscape. While many health plans and employers are still reeling from sticker shock, the potential of this promising new class of drugs to combat obesity by inducing weight loss is undeniable.
Already have an account? Sign In Now
NOT FOR REPRINT
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
Guide
Sponsored by Gallagher
Mistakes happen in retirement plan administration, but they can cost you time, money, and trust. This guide will help identify and resolve 401(k) errors quickly to save significant costs and maintain compliance.
Guide
Sponsored by ArmadaCare
Benefit Changes Are Hard. Complementing Is Easy!
Help clients meet new employee benefit needs even if they don’t want to make primary health insurance plan changes.
eBook
Sponsored by Iv m at Work
Navigating Obesity Care and GLP-1 Coverage
As obesity rates soar and new treatments like GLP-1s emerge, understanding coverage options has never been more critical. This guide can help you navigate the complexities of obesity treatment to find an effective, sustainable solution for your clients.
Copyright © 2024 ALM Global, LLC. All Rights Reserved.
Sign In
Sign In
